Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Inventory: 2014-2025

Historic Inventory for Ocular Therapeutix (OCUL) over the last 12 years, with Sep 2025 value amounting to $3.5 million.

  • Ocular Therapeutix's Inventory rose 45.03% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year increase of 45.03%. This contributed to the annual value of $3.0 million for FY2024, which is 31.89% up from last year.
  • Ocular Therapeutix's Inventory amounted to $3.5 million in Q3 2025, which was up 14.77% from $3.0 million recorded in Q2 2025.
  • Over the past 5 years, Ocular Therapeutix's Inventory peaked at $3.5 million during Q3 2025, and registered a low of $1.1 million during Q2 2021.
  • For the 3-year period, Ocular Therapeutix's Inventory averaged around $2.7 million, with its median value being $2.5 million (2024).
  • Data for Ocular Therapeutix's Inventory shows a peak YoY spiked of 66.86% (in 2023) over the last 5 years.
  • Quarterly analysis of 5 years shows Ocular Therapeutix's Inventory stood at $1.2 million in 2021, then spiked by 57.92% to $2.0 million in 2022, then rose by 16.77% to $2.3 million in 2023, then spiked by 31.89% to $3.0 million in 2024, then soared by 45.03% to $3.5 million in 2025.
  • Its Inventory stands at $3.5 million for Q3 2025, versus $3.0 million for Q2 2025 and $3.3 million for Q1 2025.